Annual Cash & Cash Equivalents
$71.42 M
-$277.18 M-79.51%
December 31, 2023
Summary
- As of February 23, 2025, SMMT annual cash & cash equivalents is $71.42 million, with the most recent change of -$277.18 million (-79.51%) on December 31, 2023.
- During the last 3 years, SMMT annual cash & cash equivalents has risen by +$5.01 million (+7.54%).
- SMMT annual cash & cash equivalents is now -79.51% below its all-time high of $348.61 million, reached on December 31, 2022.
Performance
SMMT Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Cash And Cash Equivalents
$93.78 M
+$65.34 M+229.80%
September 30, 2024
Summary
- As of February 23, 2025, SMMT quarterly cash and cash equivalents is $93.78 million, with the most recent change of +$65.34 million (+229.80%) on September 30, 2024.
- Over the past year, SMMT quarterly cash and cash equivalents has increased by +$65.34 million (+229.80%).
- SMMT quarterly cash and cash equivalents is now -73.10% below its all-time high of $348.61 million, reached on December 31, 2022.
Performance
SMMT Quarterly Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash And Cash Equivalents Formula
Cash & Cash Equivalents = Cash + Short-Term Investments
SMMT Cash And Cash Equivalents Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -79.5% | +229.8% |
| 3 y3 years | +7.5% | -73.1% |
| 5 y5 years | +102.8% | +434.4% |
SMMT Cash And Cash Equivalents Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | -79.5% | at low | -73.1% | +294.1% |
| 5 y | 5-year | -79.5% | +11.9% | -73.1% | +434.4% |
| alltime | all time | -79.5% | +3747.3% | -73.1% | >+9999.0% |
Summit Therapeutics Cash And Cash Equivalents History
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2024 | - | $93.78 M(+229.8%) |
| Jun 2024 | - | $28.43 M(-53.6%) |
| Mar 2024 | - | $61.29 M(-14.2%) |
| Dec 2023 | $71.42 M(-79.5%) | $71.42 M(+200.2%) |
| Sep 2023 | - | $23.79 M(-43.5%) |
| Jun 2023 | - | $42.12 M(-40.7%) |
| Mar 2023 | - | $70.97 M(-79.6%) |
| Dec 2022 | $348.61 M(+385.6%) | $348.61 M(+185.8%) |
| Sep 2022 | - | $121.97 M(+112.7%) |
| Jun 2022 | - | $57.34 M(-26.0%) |
| Mar 2022 | - | $77.45 M(+7.9%) |
| Dec 2021 | $71.79 M(+8.1%) | $71.79 M(-10.5%) |
| Sep 2021 | - | $80.25 M(-22.4%) |
| Jun 2021 | - | $103.39 M(+1.2%) |
| Mar 2021 | - | $102.19 M(+53.9%) |
| Dec 2020 | $66.42 M(+4.0%) | - |
| Dec 2020 | - | $66.42 M(+212.3%) |
| Sep 2020 | - | $21.27 M(-61.3%) |
| Mar 2020 | - | $54.92 M(+213.0%) |
| Dec 2019 | $63.84 M(+81.2%) | - |
| Oct 2019 | - | $17.55 M(-30.8%) |
| Jul 2019 | - | $25.37 M(-30.7%) |
| Apr 2019 | - | $36.61 M(+3.9%) |
| Jan 2019 | $35.23 M(+23.8%) | - |
| Jan 2019 | - | $35.23 M(+112.5%) |
| Oct 2018 | - | $16.58 M(-26.3%) |
| Jul 2018 | - | $22.50 M(-41.0%) |
| Apr 2018 | - | $38.12 M(+34.0%) |
| Jan 2018 | $28.45 M(-18.9%) | - |
| Jan 2018 | - | $28.45 M(-32.3%) |
| Oct 2017 | - | $42.03 M(+13.0%) |
| Jul 2017 | - | $37.18 M(+48.5%) |
| Apr 2017 | - | $25.04 M(-28.6%) |
| Jan 2017 | $35.08 M(+51.1%) | - |
| Jan 2017 | - | $35.08 M(-17.1%) |
| Oct 2016 | - | $42.29 M(+357.5%) |
| Jul 2016 | - | $9.24 M(-36.7%) |
| Apr 2016 | - | $14.60 M |
| Date | Annual | Quarterly |
|---|---|---|
| Jan 2016 | $23.22 M(+36.8%) | - |
| Jan 2016 | - | $23.22 M(-32.2%) |
| Oct 2015 | - | $34.24 M(-17.0%) |
| Jul 2015 | - | $41.24 M(-9.1%) |
| Apr 2015 | - | $45.37 M(+167.3%) |
| Jan 2015 | $16.97 M(+406.9%) | - |
| Jan 2015 | - | $16.97 M(-29.3%) |
| Oct 2014 | - | $24.01 M(-18.6%) |
| Jul 2014 | - | $29.49 M(+780.7%) |
| Jan 2014 | $3.35 M(-37.3%) | - |
| Jan 2014 | - | $3.35 M(-63.4%) |
| Jul 2013 | - | $9.15 M(+71.4%) |
| Jan 2013 | $5.34 M(+63.7%) | - |
| Jan 2013 | - | $5.34 M(-28.5%) |
| Jul 2012 | - | $7.47 M(+129.1%) |
| Jan 2012 | $3.26 M(-36.6%) | - |
| Jan 2012 | - | $3.26 M(-46.1%) |
| Jul 2011 | - | $6.04 M(+17.5%) |
| Jan 2011 | $5.14 M(-47.1%) | - |
| Jan 2011 | - | $5.14 M(-27.9%) |
| Jul 2010 | - | $7.13 M(-26.6%) |
| Jan 2010 | $9.72 M(+148.1%) | - |
| Jan 2010 | - | $9.72 M(+575.5%) |
| Jul 2009 | - | $1.44 M(-63.3%) |
| Jan 2009 | $3.92 M(-80.5%) | - |
| Jan 2009 | - | $3.92 M(-75.3%) |
| Jul 2008 | - | $15.86 M(-21.0%) |
| Jan 2008 | $20.06 M(-44.1%) | - |
| Jan 2008 | - | $20.06 M(-30.6%) |
| Jul 2007 | - | $28.91 M(-19.4%) |
| Jan 2007 | $35.87 M(+1832.4%) | - |
| Jan 2007 | - | $35.87 M(-5.0%) |
| Jul 2006 | - | $37.77 M(+1934.2%) |
| Jan 2006 | $1.86 M(-93.0%) | - |
| Jan 2006 | - | $1.86 M(-91.8%) |
| Jul 2005 | - | $22.67 M(-15.0%) |
| Jan 2005 | $26.66 M | - |
| Jan 2005 | - | $26.66 M(>+9900.0%) |
| Jul 2004 | - | $176.70 K |
FAQ
- What is Summit Therapeutics annual cash & cash equivalents?
- What is the all time high annual cash & cash equivalents for Summit Therapeutics?
- What is Summit Therapeutics annual cash & cash equivalents year-on-year change?
- What is Summit Therapeutics quarterly cash and cash equivalents?
- What is the all time high quarterly cash and cash equivalents for Summit Therapeutics?
- What is Summit Therapeutics quarterly cash and cash equivalents year-on-year change?
What is Summit Therapeutics annual cash & cash equivalents?
The current annual cash & cash equivalents of SMMT is $71.42 M
What is the all time high annual cash & cash equivalents for Summit Therapeutics?
Summit Therapeutics all-time high annual cash & cash equivalents is $348.61 M
What is Summit Therapeutics annual cash & cash equivalents year-on-year change?
Over the past year, SMMT annual cash & cash equivalents has changed by -$277.18 M (-79.51%)
What is Summit Therapeutics quarterly cash and cash equivalents?
The current quarterly cash and cash equivalents of SMMT is $93.78 M
What is the all time high quarterly cash and cash equivalents for Summit Therapeutics?
Summit Therapeutics all-time high quarterly cash and cash equivalents is $348.61 M
What is Summit Therapeutics quarterly cash and cash equivalents year-on-year change?
Over the past year, SMMT quarterly cash and cash equivalents has changed by +$65.34 M (+229.80%)